nodes	percent_of_prediction	percent_of_DWPC	metapath
Pramipexole—HTR2B—Sorafenib—liver cancer	0.264	0.606	CbGbCtD
Pramipexole—HTR2C—Sorafenib—liver cancer	0.172	0.394	CbGbCtD
Pramipexole—Abdominal pain upper—Epirubicin—liver cancer	0.000451	0.000879	CcSEcCtD
Pramipexole—Migraine—Doxorubicin—liver cancer	0.000449	0.000877	CcSEcCtD
Pramipexole—Affect lability—Doxorubicin—liver cancer	0.000449	0.000877	CcSEcCtD
Pramipexole—Hypokalaemia—Epirubicin—liver cancer	0.000449	0.000876	CcSEcCtD
Pramipexole—Diarrhoea—Sorafenib—liver cancer	0.000449	0.000876	CcSEcCtD
Pramipexole—Breast disorder—Epirubicin—liver cancer	0.000446	0.00087	CcSEcCtD
Pramipexole—Nasopharyngitis—Epirubicin—liver cancer	0.000441	0.000861	CcSEcCtD
Pramipexole—Face oedema—Doxorubicin—liver cancer	0.000441	0.00086	CcSEcCtD
Pramipexole—Gastritis—Epirubicin—liver cancer	0.000437	0.000852	CcSEcCtD
Pramipexole—Muscular weakness—Epirubicin—liver cancer	0.000435	0.000849	CcSEcCtD
Pramipexole—Cardiac arrest—Doxorubicin—liver cancer	0.000434	0.000847	CcSEcCtD
Pramipexole—Dizziness—Sorafenib—liver cancer	0.000434	0.000846	CcSEcCtD
Pramipexole—Mood swings—Doxorubicin—liver cancer	0.000432	0.000844	CcSEcCtD
Pramipexole—Abdominal distension—Epirubicin—liver cancer	0.000429	0.000837	CcSEcCtD
Pramipexole—Ataxia—Doxorubicin—liver cancer	0.000429	0.000837	CcSEcCtD
Pramipexole—Asthma—Epirubicin—liver cancer	0.000426	0.000832	CcSEcCtD
Pramipexole—Dysphagia—Epirubicin—liver cancer	0.000426	0.000832	CcSEcCtD
Pramipexole—Influenza—Epirubicin—liver cancer	0.000426	0.000832	CcSEcCtD
Pramipexole—Dehydration—Doxorubicin—liver cancer	0.000424	0.000828	CcSEcCtD
Pramipexole—Dry skin—Doxorubicin—liver cancer	0.000418	0.000816	CcSEcCtD
Pramipexole—Pancreatitis—Epirubicin—liver cancer	0.000418	0.000816	CcSEcCtD
Pramipexole—Vomiting—Sorafenib—liver cancer	0.000417	0.000814	CcSEcCtD
Pramipexole—Orthostatic hypotension—Doxorubicin—liver cancer	0.000417	0.000813	CcSEcCtD
Pramipexole—Abdominal pain upper—Doxorubicin—liver cancer	0.000417	0.000813	CcSEcCtD
Pramipexole—Hypokalaemia—Doxorubicin—liver cancer	0.000415	0.00081	CcSEcCtD
Pramipexole—Angina pectoris—Epirubicin—liver cancer	0.000415	0.00081	CcSEcCtD
Pramipexole—Rash—Sorafenib—liver cancer	0.000414	0.000807	CcSEcCtD
Pramipexole—Dermatitis—Sorafenib—liver cancer	0.000413	0.000806	CcSEcCtD
Pramipexole—Breast disorder—Doxorubicin—liver cancer	0.000412	0.000805	CcSEcCtD
Pramipexole—Headache—Sorafenib—liver cancer	0.000411	0.000802	CcSEcCtD
Pramipexole—Bronchitis—Epirubicin—liver cancer	0.00041	0.0008	CcSEcCtD
Pramipexole—Nasopharyngitis—Doxorubicin—liver cancer	0.000408	0.000796	CcSEcCtD
Pramipexole—Gastritis—Doxorubicin—liver cancer	0.000404	0.000788	CcSEcCtD
Pramipexole—Muscular weakness—Doxorubicin—liver cancer	0.000403	0.000785	CcSEcCtD
Pramipexole—Dysuria—Epirubicin—liver cancer	0.000399	0.000778	CcSEcCtD
Pramipexole—Abdominal distension—Doxorubicin—liver cancer	0.000397	0.000775	CcSEcCtD
Pramipexole—Upper respiratory tract infection—Epirubicin—liver cancer	0.000396	0.000773	CcSEcCtD
Pramipexole—Influenza—Doxorubicin—liver cancer	0.000394	0.00077	CcSEcCtD
Pramipexole—Asthma—Doxorubicin—liver cancer	0.000394	0.00077	CcSEcCtD
Pramipexole—Dysphagia—Doxorubicin—liver cancer	0.000394	0.00077	CcSEcCtD
Pramipexole—Pollakiuria—Epirubicin—liver cancer	0.000394	0.000768	CcSEcCtD
Pramipexole—Nausea—Sorafenib—liver cancer	0.00039	0.00076	CcSEcCtD
Pramipexole—Photosensitivity reaction—Epirubicin—liver cancer	0.000389	0.000759	CcSEcCtD
Pramipexole—Weight increased—Epirubicin—liver cancer	0.000388	0.000757	CcSEcCtD
Pramipexole—Pancreatitis—Doxorubicin—liver cancer	0.000387	0.000755	CcSEcCtD
Pramipexole—Weight decreased—Epirubicin—liver cancer	0.000386	0.000753	CcSEcCtD
Pramipexole—Hyperglycaemia—Epirubicin—liver cancer	0.000385	0.00075	CcSEcCtD
Pramipexole—Angina pectoris—Doxorubicin—liver cancer	0.000384	0.00075	CcSEcCtD
Pramipexole—Pneumonia—Epirubicin—liver cancer	0.000382	0.000746	CcSEcCtD
Pramipexole—Drowsiness—Epirubicin—liver cancer	0.00038	0.000742	CcSEcCtD
Pramipexole—Infestation NOS—Epirubicin—liver cancer	0.00038	0.000742	CcSEcCtD
Pramipexole—Infestation—Epirubicin—liver cancer	0.00038	0.000742	CcSEcCtD
Pramipexole—Bronchitis—Doxorubicin—liver cancer	0.000379	0.00074	CcSEcCtD
Pramipexole—Renal failure—Epirubicin—liver cancer	0.000374	0.000729	CcSEcCtD
Pramipexole—Neuropathy peripheral—Epirubicin—liver cancer	0.000373	0.000727	CcSEcCtD
Pramipexole—Urinary tract infection—Epirubicin—liver cancer	0.000369	0.000721	CcSEcCtD
Pramipexole—Conjunctivitis—Epirubicin—liver cancer	0.000369	0.000721	CcSEcCtD
Pramipexole—Dysuria—Doxorubicin—liver cancer	0.000369	0.00072	CcSEcCtD
Pramipexole—Upper respiratory tract infection—Doxorubicin—liver cancer	0.000367	0.000715	CcSEcCtD
Pramipexole—Sweating—Epirubicin—liver cancer	0.000364	0.000711	CcSEcCtD
Pramipexole—Pollakiuria—Doxorubicin—liver cancer	0.000364	0.000711	CcSEcCtD
Pramipexole—Haematuria—Epirubicin—liver cancer	0.000362	0.000707	CcSEcCtD
Pramipexole—Photosensitivity reaction—Doxorubicin—liver cancer	0.00036	0.000703	CcSEcCtD
Pramipexole—Hepatobiliary disease—Epirubicin—liver cancer	0.000359	0.000701	CcSEcCtD
Pramipexole—Weight increased—Doxorubicin—liver cancer	0.000359	0.0007	CcSEcCtD
Pramipexole—Epistaxis—Epirubicin—liver cancer	0.000359	0.0007	CcSEcCtD
Pramipexole—Weight decreased—Doxorubicin—liver cancer	0.000357	0.000696	CcSEcCtD
Pramipexole—Sinusitis—Epirubicin—liver cancer	0.000357	0.000696	CcSEcCtD
Pramipexole—Hyperglycaemia—Doxorubicin—liver cancer	0.000356	0.000694	CcSEcCtD
Pramipexole—Pneumonia—Doxorubicin—liver cancer	0.000354	0.00069	CcSEcCtD
Pramipexole—Infestation—Doxorubicin—liver cancer	0.000352	0.000686	CcSEcCtD
Pramipexole—Drowsiness—Doxorubicin—liver cancer	0.000352	0.000686	CcSEcCtD
Pramipexole—Infestation NOS—Doxorubicin—liver cancer	0.000352	0.000686	CcSEcCtD
Pramipexole—Bradycardia—Epirubicin—liver cancer	0.000347	0.000678	CcSEcCtD
Pramipexole—Renal failure—Doxorubicin—liver cancer	0.000346	0.000675	CcSEcCtD
Pramipexole—Neuropathy peripheral—Doxorubicin—liver cancer	0.000345	0.000673	CcSEcCtD
Pramipexole—Rhinitis—Epirubicin—liver cancer	0.000342	0.000668	CcSEcCtD
Pramipexole—Conjunctivitis—Doxorubicin—liver cancer	0.000342	0.000667	CcSEcCtD
Pramipexole—Urinary tract infection—Doxorubicin—liver cancer	0.000342	0.000667	CcSEcCtD
Pramipexole—Hypoaesthesia—Epirubicin—liver cancer	0.00034	0.000663	CcSEcCtD
Pramipexole—Pharyngitis—Epirubicin—liver cancer	0.000339	0.000661	CcSEcCtD
Pramipexole—Sweating—Doxorubicin—liver cancer	0.000337	0.000658	CcSEcCtD
Pramipexole—Urinary tract disorder—Epirubicin—liver cancer	0.000337	0.000658	CcSEcCtD
Pramipexole—Oedema peripheral—Epirubicin—liver cancer	0.000336	0.000656	CcSEcCtD
Pramipexole—Haematuria—Doxorubicin—liver cancer	0.000335	0.000654	CcSEcCtD
Pramipexole—Connective tissue disorder—Epirubicin—liver cancer	0.000335	0.000654	CcSEcCtD
Pramipexole—Urethral disorder—Epirubicin—liver cancer	0.000334	0.000653	CcSEcCtD
Pramipexole—Hepatobiliary disease—Doxorubicin—liver cancer	0.000333	0.000649	CcSEcCtD
Pramipexole—Epistaxis—Doxorubicin—liver cancer	0.000332	0.000647	CcSEcCtD
Pramipexole—Sinusitis—Doxorubicin—liver cancer	0.00033	0.000644	CcSEcCtD
Pramipexole—Visual impairment—Epirubicin—liver cancer	0.000329	0.000642	CcSEcCtD
Pramipexole—Bradycardia—Doxorubicin—liver cancer	0.000321	0.000627	CcSEcCtD
Pramipexole—Eye disorder—Epirubicin—liver cancer	0.000319	0.000622	CcSEcCtD
Pramipexole—Tinnitus—Epirubicin—liver cancer	0.000318	0.000621	CcSEcCtD
Pramipexole—Flushing—Epirubicin—liver cancer	0.000317	0.000618	CcSEcCtD
Pramipexole—Cardiac disorder—Epirubicin—liver cancer	0.000317	0.000618	CcSEcCtD
Pramipexole—Rhinitis—Doxorubicin—liver cancer	0.000317	0.000618	CcSEcCtD
Pramipexole—Hypoaesthesia—Doxorubicin—liver cancer	0.000314	0.000613	CcSEcCtD
Pramipexole—Pharyngitis—Doxorubicin—liver cancer	0.000313	0.000611	CcSEcCtD
Pramipexole—Urinary tract disorder—Doxorubicin—liver cancer	0.000312	0.000608	CcSEcCtD
Pramipexole—Oedema peripheral—Doxorubicin—liver cancer	0.000311	0.000607	CcSEcCtD
Pramipexole—Connective tissue disorder—Doxorubicin—liver cancer	0.00031	0.000605	CcSEcCtD
Pramipexole—Angiopathy—Epirubicin—liver cancer	0.00031	0.000604	CcSEcCtD
Pramipexole—Urethral disorder—Doxorubicin—liver cancer	0.00031	0.000604	CcSEcCtD
Pramipexole—Immune system disorder—Epirubicin—liver cancer	0.000308	0.000601	CcSEcCtD
Pramipexole—Mediastinal disorder—Epirubicin—liver cancer	0.000308	0.0006	CcSEcCtD
Pramipexole—Chills—Epirubicin—liver cancer	0.000306	0.000597	CcSEcCtD
Pramipexole—Visual impairment—Doxorubicin—liver cancer	0.000304	0.000594	CcSEcCtD
Pramipexole—Alopecia—Epirubicin—liver cancer	0.000302	0.000588	CcSEcCtD
Pramipexole—Mental disorder—Epirubicin—liver cancer	0.000299	0.000583	CcSEcCtD
Pramipexole—Erythema—Epirubicin—liver cancer	0.000297	0.00058	CcSEcCtD
Pramipexole—Malnutrition—Epirubicin—liver cancer	0.000297	0.00058	CcSEcCtD
Pramipexole—Eye disorder—Doxorubicin—liver cancer	0.000295	0.000576	CcSEcCtD
Pramipexole—Tinnitus—Doxorubicin—liver cancer	0.000294	0.000574	CcSEcCtD
Pramipexole—Flushing—Doxorubicin—liver cancer	0.000293	0.000572	CcSEcCtD
Pramipexole—Cardiac disorder—Doxorubicin—liver cancer	0.000293	0.000572	CcSEcCtD
Pramipexole—Flatulence—Epirubicin—liver cancer	0.000293	0.000571	CcSEcCtD
Pramipexole—Tension—Epirubicin—liver cancer	0.000291	0.000569	CcSEcCtD
Pramipexole—Dysgeusia—Epirubicin—liver cancer	0.000291	0.000568	CcSEcCtD
Pramipexole—Nervousness—Epirubicin—liver cancer	0.000289	0.000563	CcSEcCtD
Pramipexole—Back pain—Epirubicin—liver cancer	0.000287	0.000561	CcSEcCtD
Pramipexole—Angiopathy—Doxorubicin—liver cancer	0.000286	0.000559	CcSEcCtD
Pramipexole—Muscle spasms—Epirubicin—liver cancer	0.000286	0.000557	CcSEcCtD
Pramipexole—Immune system disorder—Doxorubicin—liver cancer	0.000285	0.000556	CcSEcCtD
Pramipexole—Mediastinal disorder—Doxorubicin—liver cancer	0.000285	0.000555	CcSEcCtD
Pramipexole—Chills—Doxorubicin—liver cancer	0.000283	0.000553	CcSEcCtD
Pramipexole—Vision blurred—Epirubicin—liver cancer	0.00028	0.000546	CcSEcCtD
Pramipexole—Alopecia—Doxorubicin—liver cancer	0.000279	0.000544	CcSEcCtD
Pramipexole—Mental disorder—Doxorubicin—liver cancer	0.000277	0.00054	CcSEcCtD
Pramipexole—Ill-defined disorder—Epirubicin—liver cancer	0.000276	0.000538	CcSEcCtD
Pramipexole—Erythema—Doxorubicin—liver cancer	0.000275	0.000536	CcSEcCtD
Pramipexole—Malnutrition—Doxorubicin—liver cancer	0.000275	0.000536	CcSEcCtD
Pramipexole—Anaemia—Epirubicin—liver cancer	0.000275	0.000536	CcSEcCtD
Pramipexole—Agitation—Epirubicin—liver cancer	0.000273	0.000533	CcSEcCtD
Pramipexole—Flatulence—Doxorubicin—liver cancer	0.000271	0.000528	CcSEcCtD
Pramipexole—Tension—Doxorubicin—liver cancer	0.00027	0.000526	CcSEcCtD
Pramipexole—Dysgeusia—Doxorubicin—liver cancer	0.000269	0.000525	CcSEcCtD
Pramipexole—Malaise—Epirubicin—liver cancer	0.000268	0.000523	CcSEcCtD
Pramipexole—Nervousness—Doxorubicin—liver cancer	0.000267	0.000521	CcSEcCtD
Pramipexole—Vertigo—Epirubicin—liver cancer	0.000267	0.000521	CcSEcCtD
Pramipexole—Syncope—Epirubicin—liver cancer	0.000266	0.00052	CcSEcCtD
Pramipexole—Leukopenia—Epirubicin—liver cancer	0.000266	0.000519	CcSEcCtD
Pramipexole—Back pain—Doxorubicin—liver cancer	0.000266	0.000519	CcSEcCtD
Pramipexole—Muscle spasms—Doxorubicin—liver cancer	0.000264	0.000516	CcSEcCtD
Pramipexole—Palpitations—Epirubicin—liver cancer	0.000263	0.000512	CcSEcCtD
Pramipexole—Loss of consciousness—Epirubicin—liver cancer	0.000261	0.000509	CcSEcCtD
Pramipexole—Cough—Epirubicin—liver cancer	0.000259	0.000506	CcSEcCtD
Pramipexole—Vision blurred—Doxorubicin—liver cancer	0.000259	0.000505	CcSEcCtD
Pramipexole—Convulsion—Epirubicin—liver cancer	0.000257	0.000502	CcSEcCtD
Pramipexole—Hypertension—Epirubicin—liver cancer	0.000256	0.0005	CcSEcCtD
Pramipexole—Ill-defined disorder—Doxorubicin—liver cancer	0.000255	0.000498	CcSEcCtD
Pramipexole—Anaemia—Doxorubicin—liver cancer	0.000254	0.000496	CcSEcCtD
Pramipexole—Arthralgia—Epirubicin—liver cancer	0.000253	0.000493	CcSEcCtD
Pramipexole—Myalgia—Epirubicin—liver cancer	0.000253	0.000493	CcSEcCtD
Pramipexole—Chest pain—Epirubicin—liver cancer	0.000253	0.000493	CcSEcCtD
Pramipexole—Agitation—Doxorubicin—liver cancer	0.000253	0.000493	CcSEcCtD
Pramipexole—Anxiety—Epirubicin—liver cancer	0.000252	0.000492	CcSEcCtD
Pramipexole—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—liver cancer	0.000251	0.00049	CcSEcCtD
Pramipexole—Discomfort—Epirubicin—liver cancer	0.00025	0.000488	CcSEcCtD
Pramipexole—Malaise—Doxorubicin—liver cancer	0.000248	0.000484	CcSEcCtD
Pramipexole—Dry mouth—Epirubicin—liver cancer	0.000247	0.000483	CcSEcCtD
Pramipexole—Vertigo—Doxorubicin—liver cancer	0.000247	0.000482	CcSEcCtD
Pramipexole—Syncope—Doxorubicin—liver cancer	0.000246	0.000481	CcSEcCtD
Pramipexole—Leukopenia—Doxorubicin—liver cancer	0.000246	0.00048	CcSEcCtD
Pramipexole—Confusional state—Epirubicin—liver cancer	0.000244	0.000477	CcSEcCtD
Pramipexole—Palpitations—Doxorubicin—liver cancer	0.000243	0.000474	CcSEcCtD
Pramipexole—Oedema—Epirubicin—liver cancer	0.000242	0.000473	CcSEcCtD
Pramipexole—Loss of consciousness—Doxorubicin—liver cancer	0.000242	0.000471	CcSEcCtD
Pramipexole—Infection—Epirubicin—liver cancer	0.000241	0.00047	CcSEcCtD
Pramipexole—Cough—Doxorubicin—liver cancer	0.00024	0.000468	CcSEcCtD
Pramipexole—Shock—Epirubicin—liver cancer	0.000239	0.000465	CcSEcCtD
Pramipexole—Convulsion—Doxorubicin—liver cancer	0.000238	0.000465	CcSEcCtD
Pramipexole—Nervous system disorder—Epirubicin—liver cancer	0.000238	0.000464	CcSEcCtD
Pramipexole—Thrombocytopenia—Epirubicin—liver cancer	0.000237	0.000463	CcSEcCtD
Pramipexole—Hypertension—Doxorubicin—liver cancer	0.000237	0.000463	CcSEcCtD
Pramipexole—Tachycardia—Epirubicin—liver cancer	0.000237	0.000462	CcSEcCtD
Pramipexole—Skin disorder—Epirubicin—liver cancer	0.000235	0.000459	CcSEcCtD
Pramipexole—Hyperhidrosis—Epirubicin—liver cancer	0.000234	0.000457	CcSEcCtD
Pramipexole—Arthralgia—Doxorubicin—liver cancer	0.000234	0.000457	CcSEcCtD
Pramipexole—Myalgia—Doxorubicin—liver cancer	0.000234	0.000457	CcSEcCtD
Pramipexole—Chest pain—Doxorubicin—liver cancer	0.000234	0.000457	CcSEcCtD
Pramipexole—Anxiety—Doxorubicin—liver cancer	0.000233	0.000455	CcSEcCtD
Pramipexole—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—liver cancer	0.000232	0.000453	CcSEcCtD
Pramipexole—Discomfort—Doxorubicin—liver cancer	0.000231	0.000451	CcSEcCtD
Pramipexole—Anorexia—Epirubicin—liver cancer	0.000231	0.000451	CcSEcCtD
Pramipexole—Dry mouth—Doxorubicin—liver cancer	0.000229	0.000447	CcSEcCtD
Pramipexole—Hypotension—Epirubicin—liver cancer	0.000227	0.000442	CcSEcCtD
Pramipexole—Confusional state—Doxorubicin—liver cancer	0.000226	0.000441	CcSEcCtD
Pramipexole—Oedema—Doxorubicin—liver cancer	0.000224	0.000438	CcSEcCtD
Pramipexole—Infection—Doxorubicin—liver cancer	0.000223	0.000435	CcSEcCtD
Pramipexole—Musculoskeletal discomfort—Epirubicin—liver cancer	0.000221	0.000431	CcSEcCtD
Pramipexole—Shock—Doxorubicin—liver cancer	0.000221	0.000431	CcSEcCtD
Pramipexole—Nervous system disorder—Doxorubicin—liver cancer	0.00022	0.000429	CcSEcCtD
Pramipexole—Thrombocytopenia—Doxorubicin—liver cancer	0.00022	0.000429	CcSEcCtD
Pramipexole—Insomnia—Epirubicin—liver cancer	0.000219	0.000428	CcSEcCtD
Pramipexole—Tachycardia—Doxorubicin—liver cancer	0.000219	0.000427	CcSEcCtD
Pramipexole—Skin disorder—Doxorubicin—liver cancer	0.000218	0.000425	CcSEcCtD
Pramipexole—Paraesthesia—Epirubicin—liver cancer	0.000218	0.000425	CcSEcCtD
Pramipexole—Hyperhidrosis—Doxorubicin—liver cancer	0.000217	0.000423	CcSEcCtD
Pramipexole—Dyspnoea—Epirubicin—liver cancer	0.000216	0.000422	CcSEcCtD
Pramipexole—Somnolence—Epirubicin—liver cancer	0.000216	0.000421	CcSEcCtD
Pramipexole—Anorexia—Doxorubicin—liver cancer	0.000214	0.000417	CcSEcCtD
Pramipexole—Dyspepsia—Epirubicin—liver cancer	0.000213	0.000416	CcSEcCtD
Pramipexole—Decreased appetite—Epirubicin—liver cancer	0.000211	0.000411	CcSEcCtD
Pramipexole—Hypotension—Doxorubicin—liver cancer	0.00021	0.000409	CcSEcCtD
Pramipexole—Gastrointestinal disorder—Epirubicin—liver cancer	0.000209	0.000408	CcSEcCtD
Pramipexole—Fatigue—Epirubicin—liver cancer	0.000209	0.000408	CcSEcCtD
Pramipexole—Constipation—Epirubicin—liver cancer	0.000207	0.000405	CcSEcCtD
Pramipexole—Pain—Epirubicin—liver cancer	0.000207	0.000405	CcSEcCtD
Pramipexole—Musculoskeletal discomfort—Doxorubicin—liver cancer	0.000204	0.000399	CcSEcCtD
Pramipexole—Insomnia—Doxorubicin—liver cancer	0.000203	0.000396	CcSEcCtD
Pramipexole—Paraesthesia—Doxorubicin—liver cancer	0.000201	0.000393	CcSEcCtD
Pramipexole—Dyspnoea—Doxorubicin—liver cancer	0.0002	0.00039	CcSEcCtD
Pramipexole—Feeling abnormal—Epirubicin—liver cancer	0.0002	0.00039	CcSEcCtD
Pramipexole—Somnolence—Doxorubicin—liver cancer	0.000199	0.000389	CcSEcCtD
Pramipexole—Gastrointestinal pain—Epirubicin—liver cancer	0.000198	0.000387	CcSEcCtD
Pramipexole—Dyspepsia—Doxorubicin—liver cancer	0.000197	0.000385	CcSEcCtD
Pramipexole—Decreased appetite—Doxorubicin—liver cancer	0.000195	0.00038	CcSEcCtD
Pramipexole—Gastrointestinal disorder—Doxorubicin—liver cancer	0.000194	0.000378	CcSEcCtD
Pramipexole—Fatigue—Doxorubicin—liver cancer	0.000193	0.000377	CcSEcCtD
Pramipexole—Urticaria—Epirubicin—liver cancer	0.000193	0.000376	CcSEcCtD
Pramipexole—Constipation—Doxorubicin—liver cancer	0.000192	0.000374	CcSEcCtD
Pramipexole—Pain—Doxorubicin—liver cancer	0.000192	0.000374	CcSEcCtD
Pramipexole—Abdominal pain—Epirubicin—liver cancer	0.000192	0.000374	CcSEcCtD
Pramipexole—Body temperature increased—Epirubicin—liver cancer	0.000192	0.000374	CcSEcCtD
Pramipexole—Feeling abnormal—Doxorubicin—liver cancer	0.000185	0.000361	CcSEcCtD
Pramipexole—Gastrointestinal pain—Doxorubicin—liver cancer	0.000183	0.000358	CcSEcCtD
Pramipexole—Hypersensitivity—Epirubicin—liver cancer	0.000179	0.000349	CcSEcCtD
Pramipexole—Urticaria—Doxorubicin—liver cancer	0.000178	0.000348	CcSEcCtD
Pramipexole—Abdominal pain—Doxorubicin—liver cancer	0.000177	0.000346	CcSEcCtD
Pramipexole—Body temperature increased—Doxorubicin—liver cancer	0.000177	0.000346	CcSEcCtD
Pramipexole—Asthenia—Epirubicin—liver cancer	0.000174	0.000339	CcSEcCtD
Pramipexole—Pruritus—Epirubicin—liver cancer	0.000172	0.000335	CcSEcCtD
Pramipexole—Diarrhoea—Epirubicin—liver cancer	0.000166	0.000324	CcSEcCtD
Pramipexole—Hypersensitivity—Doxorubicin—liver cancer	0.000165	0.000322	CcSEcCtD
Pramipexole—Asthenia—Doxorubicin—liver cancer	0.000161	0.000314	CcSEcCtD
Pramipexole—Dizziness—Epirubicin—liver cancer	0.00016	0.000313	CcSEcCtD
Pramipexole—Pruritus—Doxorubicin—liver cancer	0.000159	0.00031	CcSEcCtD
Pramipexole—Vomiting—Epirubicin—liver cancer	0.000154	0.000301	CcSEcCtD
Pramipexole—Diarrhoea—Doxorubicin—liver cancer	0.000153	0.000299	CcSEcCtD
Pramipexole—Rash—Epirubicin—liver cancer	0.000153	0.000298	CcSEcCtD
Pramipexole—Dermatitis—Epirubicin—liver cancer	0.000153	0.000298	CcSEcCtD
Pramipexole—Headache—Epirubicin—liver cancer	0.000152	0.000296	CcSEcCtD
Pramipexole—Dizziness—Doxorubicin—liver cancer	0.000148	0.000289	CcSEcCtD
Pramipexole—Nausea—Epirubicin—liver cancer	0.000144	0.000281	CcSEcCtD
Pramipexole—Vomiting—Doxorubicin—liver cancer	0.000143	0.000278	CcSEcCtD
Pramipexole—Rash—Doxorubicin—liver cancer	0.000141	0.000276	CcSEcCtD
Pramipexole—Dermatitis—Doxorubicin—liver cancer	0.000141	0.000276	CcSEcCtD
Pramipexole—Headache—Doxorubicin—liver cancer	0.000141	0.000274	CcSEcCtD
Pramipexole—Nausea—Doxorubicin—liver cancer	0.000133	0.00026	CcSEcCtD
Pramipexole—HTR2A—GPCR downstream signaling—PIK3CA—liver cancer	7.35e-06	0.000143	CbGpPWpGaD
Pramipexole—DRD1—Signaling by GPCR—AKT1—liver cancer	7.34e-06	0.000143	CbGpPWpGaD
Pramipexole—HTR2A—Signaling Pathways—SERPINE1—liver cancer	7.34e-06	0.000143	CbGpPWpGaD
Pramipexole—ADRA2B—Signaling Pathways—CDKN1B—liver cancer	7.28e-06	0.000142	CbGpPWpGaD
Pramipexole—HTR2A—Signaling by GPCR—KRAS—liver cancer	7.27e-06	0.000142	CbGpPWpGaD
Pramipexole—DRD3—Signaling Pathways—MAPK8—liver cancer	7.26e-06	0.000142	CbGpPWpGaD
Pramipexole—ADRA2C—Signaling Pathways—MTOR—liver cancer	7.25e-06	0.000141	CbGpPWpGaD
Pramipexole—ADRA2C—Signaling Pathways—PIK3CB—liver cancer	7.25e-06	0.000141	CbGpPWpGaD
Pramipexole—DRD3—Signaling by GPCR—AKT1—liver cancer	7.24e-06	0.000141	CbGpPWpGaD
Pramipexole—ADRA2A—Signaling Pathways—BRAF—liver cancer	7.22e-06	0.000141	CbGpPWpGaD
Pramipexole—HTR1D—Signaling Pathways—MYC—liver cancer	7.21e-06	0.000141	CbGpPWpGaD
Pramipexole—HTR2B—Signaling Pathways—VEGFA—liver cancer	7.21e-06	0.000141	CbGpPWpGaD
Pramipexole—ADRA2B—GPCR downstream signaling—AKT1—liver cancer	7.2e-06	0.000141	CbGpPWpGaD
Pramipexole—HTR1D—Signaling Pathways—TGFB1—liver cancer	7.19e-06	0.00014	CbGpPWpGaD
Pramipexole—HTR1A—Signaling by GPCR—HRAS—liver cancer	7.15e-06	0.00014	CbGpPWpGaD
Pramipexole—HTR2B—Signaling Pathways—STAT3—liver cancer	7.14e-06	0.000139	CbGpPWpGaD
Pramipexole—ADRA2B—Signaling Pathways—CASP3—liver cancer	7.14e-06	0.000139	CbGpPWpGaD
Pramipexole—ADRA2B—Signaling Pathways—IL2—liver cancer	7.12e-06	0.000139	CbGpPWpGaD
Pramipexole—HTR2C—Signaling by GPCR—HRAS—liver cancer	7.11e-06	0.000139	CbGpPWpGaD
Pramipexole—ADRA2B—Signaling by GPCR—IL6—liver cancer	7.09e-06	0.000138	CbGpPWpGaD
Pramipexole—DRD5—Signaling Pathways—IL6—liver cancer	7.08e-06	0.000138	CbGpPWpGaD
Pramipexole—HTR1B—Signaling Pathways—MYC—liver cancer	7.06e-06	0.000138	CbGpPWpGaD
Pramipexole—HTR1B—Signaling Pathways—TGFB1—liver cancer	7.04e-06	0.000137	CbGpPWpGaD
Pramipexole—ADRA2A—Metabolism—PIK3CB—liver cancer	7.04e-06	0.000137	CbGpPWpGaD
Pramipexole—HTR1A—Signaling Pathways—CDKN1B—liver cancer	7.03e-06	0.000137	CbGpPWpGaD
Pramipexole—HTR2C—Signaling Pathways—CDKN1B—liver cancer	6.99e-06	0.000136	CbGpPWpGaD
Pramipexole—HTR1A—GPCR downstream signaling—AKT1—liver cancer	6.95e-06	0.000136	CbGpPWpGaD
Pramipexole—DRD4—Signaling Pathways—MYC—liver cancer	6.95e-06	0.000136	CbGpPWpGaD
Pramipexole—ADRA2B—Signaling Pathways—CCND1—liver cancer	6.95e-06	0.000136	CbGpPWpGaD
Pramipexole—ADRA2B—Signaling Pathways—JUN—liver cancer	6.93e-06	0.000135	CbGpPWpGaD
Pramipexole—DRD4—Signaling Pathways—TGFB1—liver cancer	6.93e-06	0.000135	CbGpPWpGaD
Pramipexole—ADRA2C—Signaling by GPCR—HRAS—liver cancer	6.92e-06	0.000135	CbGpPWpGaD
Pramipexole—HTR2C—GPCR downstream signaling—AKT1—liver cancer	6.92e-06	0.000135	CbGpPWpGaD
Pramipexole—HTR1A—Signaling Pathways—CASP3—liver cancer	6.89e-06	0.000134	CbGpPWpGaD
Pramipexole—ADRA2B—Signaling Pathways—CTNNB1—liver cancer	6.88e-06	0.000134	CbGpPWpGaD
Pramipexole—HTR1A—Signaling Pathways—IL2—liver cancer	6.88e-06	0.000134	CbGpPWpGaD
Pramipexole—HTR2C—Signaling Pathways—CASP3—liver cancer	6.85e-06	0.000134	CbGpPWpGaD
Pramipexole—HTR1A—Signaling by GPCR—IL6—liver cancer	6.84e-06	0.000134	CbGpPWpGaD
Pramipexole—HTR2C—Signaling Pathways—IL2—liver cancer	6.84e-06	0.000134	CbGpPWpGaD
Pramipexole—HTR2C—Signaling by GPCR—IL6—liver cancer	6.81e-06	0.000133	CbGpPWpGaD
Pramipexole—ADRA2C—Signaling Pathways—CDKN1B—liver cancer	6.8e-06	0.000133	CbGpPWpGaD
Pramipexole—DRD1—Signaling Pathways—VEGFA—liver cancer	6.8e-06	0.000133	CbGpPWpGaD
Pramipexole—DRD2—Signaling by GPCR—PIK3CA—liver cancer	6.79e-06	0.000132	CbGpPWpGaD
Pramipexole—ADRA2A—Signaling Pathways—PIK3CD—liver cancer	6.75e-06	0.000132	CbGpPWpGaD
Pramipexole—ADRA2B—Signaling Pathways—MMP9—liver cancer	6.74e-06	0.000132	CbGpPWpGaD
Pramipexole—DRD2—Signaling Pathways—RAF1—liver cancer	6.73e-06	0.000131	CbGpPWpGaD
Pramipexole—DRD1—Signaling Pathways—STAT3—liver cancer	6.73e-06	0.000131	CbGpPWpGaD
Pramipexole—ADRA2C—GPCR downstream signaling—AKT1—liver cancer	6.73e-06	0.000131	CbGpPWpGaD
Pramipexole—ADRA2B—Signaling Pathways—CDKN1A—liver cancer	6.72e-06	0.000131	CbGpPWpGaD
Pramipexole—DRD3—Signaling Pathways—VEGFA—liver cancer	6.71e-06	0.000131	CbGpPWpGaD
Pramipexole—HTR1A—Signaling Pathways—CCND1—liver cancer	6.7e-06	0.000131	CbGpPWpGaD
Pramipexole—HTR1A—Signaling Pathways—JUN—liver cancer	6.69e-06	0.000131	CbGpPWpGaD
Pramipexole—ADRA2A—GPCR downstream signaling—PIK3CA—liver cancer	6.69e-06	0.000131	CbGpPWpGaD
Pramipexole—ADRA2A—Signaling Pathways—SERPINE1—liver cancer	6.68e-06	0.00013	CbGpPWpGaD
Pramipexole—HTR2A—Signaling by GPCR—PIK3CA—liver cancer	6.68e-06	0.00013	CbGpPWpGaD
Pramipexole—HTR2C—Signaling Pathways—CCND1—liver cancer	6.67e-06	0.00013	CbGpPWpGaD
Pramipexole—ADRA2C—Signaling Pathways—CASP3—liver cancer	6.67e-06	0.00013	CbGpPWpGaD
Pramipexole—HTR1D—Signaling Pathways—KRAS—liver cancer	6.66e-06	0.00013	CbGpPWpGaD
Pramipexole—HTR2C—Signaling Pathways—JUN—liver cancer	6.66e-06	0.00013	CbGpPWpGaD
Pramipexole—ADRA2C—Signaling Pathways—IL2—liver cancer	6.66e-06	0.00013	CbGpPWpGaD
Pramipexole—DRD3—Signaling Pathways—STAT3—liver cancer	6.64e-06	0.00013	CbGpPWpGaD
Pramipexole—HTR1A—Signaling Pathways—CTNNB1—liver cancer	6.64e-06	0.00013	CbGpPWpGaD
Pramipexole—HTR2B—Signaling Pathways—MYC—liver cancer	6.63e-06	0.000129	CbGpPWpGaD
Pramipexole—HTR2A—Signaling Pathways—RAF1—liver cancer	6.63e-06	0.000129	CbGpPWpGaD
Pramipexole—ADRA2C—Signaling by GPCR—IL6—liver cancer	6.62e-06	0.000129	CbGpPWpGaD
Pramipexole—HTR2B—Signaling Pathways—TGFB1—liver cancer	6.62e-06	0.000129	CbGpPWpGaD
Pramipexole—ADRA2A—Signaling by GPCR—KRAS—liver cancer	6.61e-06	0.000129	CbGpPWpGaD
Pramipexole—HTR2C—Signaling Pathways—CTNNB1—liver cancer	6.61e-06	0.000129	CbGpPWpGaD
Pramipexole—DRD2—Signaling Pathways—MTOR—liver cancer	6.58e-06	0.000128	CbGpPWpGaD
Pramipexole—DRD2—Signaling Pathways—PIK3CB—liver cancer	6.58e-06	0.000128	CbGpPWpGaD
Pramipexole—ADRA2B—Signaling Pathways—MAPK8—liver cancer	6.56e-06	0.000128	CbGpPWpGaD
Pramipexole—ADRA2B—Signaling by GPCR—AKT1—liver cancer	6.54e-06	0.000128	CbGpPWpGaD
Pramipexole—DRD5—Signaling Pathways—AKT1—liver cancer	6.53e-06	0.000127	CbGpPWpGaD
Pramipexole—HTR1B—Signaling Pathways—KRAS—liver cancer	6.52e-06	0.000127	CbGpPWpGaD
Pramipexole—HTR1A—Signaling Pathways—MMP9—liver cancer	6.51e-06	0.000127	CbGpPWpGaD
Pramipexole—ADRA2C—Signaling Pathways—CCND1—liver cancer	6.49e-06	0.000127	CbGpPWpGaD
Pramipexole—HTR1A—Signaling Pathways—CDKN1A—liver cancer	6.49e-06	0.000127	CbGpPWpGaD
Pramipexole—HTR2C—Signaling Pathways—MMP9—liver cancer	6.48e-06	0.000126	CbGpPWpGaD
Pramipexole—ADRA2C—Signaling Pathways—JUN—liver cancer	6.47e-06	0.000126	CbGpPWpGaD
Pramipexole—HTR2A—Signaling Pathways—MTOR—liver cancer	6.47e-06	0.000126	CbGpPWpGaD
Pramipexole—HTR2A—Signaling Pathways—PIK3CB—liver cancer	6.47e-06	0.000126	CbGpPWpGaD
Pramipexole—HTR2C—Signaling Pathways—CDKN1A—liver cancer	6.45e-06	0.000126	CbGpPWpGaD
Pramipexole—ADRA2C—Signaling Pathways—CTNNB1—liver cancer	6.42e-06	0.000125	CbGpPWpGaD
Pramipexole—DRD4—Signaling Pathways—KRAS—liver cancer	6.42e-06	0.000125	CbGpPWpGaD
Pramipexole—HTR1A—Signaling Pathways—MAPK8—liver cancer	6.33e-06	0.000124	CbGpPWpGaD
Pramipexole—HTR1A—Signaling by GPCR—AKT1—liver cancer	6.31e-06	0.000123	CbGpPWpGaD
Pramipexole—ADRA2C—Signaling Pathways—MMP9—liver cancer	6.3e-06	0.000123	CbGpPWpGaD
Pramipexole—HTR2C—Signaling Pathways—MAPK8—liver cancer	6.3e-06	0.000123	CbGpPWpGaD
Pramipexole—HTR2C—Signaling by GPCR—AKT1—liver cancer	6.28e-06	0.000123	CbGpPWpGaD
Pramipexole—DRD2—Signaling by GPCR—HRAS—liver cancer	6.28e-06	0.000123	CbGpPWpGaD
Pramipexole—ADRA2C—Signaling Pathways—CDKN1A—liver cancer	6.28e-06	0.000122	CbGpPWpGaD
Pramipexole—DRD1—Signaling Pathways—MYC—liver cancer	6.25e-06	0.000122	CbGpPWpGaD
Pramipexole—DRD1—Signaling Pathways—TGFB1—liver cancer	6.24e-06	0.000122	CbGpPWpGaD
Pramipexole—HTR2A—Signaling by GPCR—HRAS—liver cancer	6.18e-06	0.000121	CbGpPWpGaD
Pramipexole—DRD2—Signaling Pathways—CDKN1B—liver cancer	6.17e-06	0.00012	CbGpPWpGaD
Pramipexole—DRD3—Signaling Pathways—MYC—liver cancer	6.17e-06	0.00012	CbGpPWpGaD
Pramipexole—DRD3—Signaling Pathways—TGFB1—liver cancer	6.16e-06	0.00012	CbGpPWpGaD
Pramipexole—HTR2B—Signaling Pathways—KRAS—liver cancer	6.13e-06	0.00012	CbGpPWpGaD
Pramipexole—ADRA2C—Signaling Pathways—MAPK8—liver cancer	6.13e-06	0.00012	CbGpPWpGaD
Pramipexole—HTR1D—Signaling Pathways—PIK3CA—liver cancer	6.12e-06	0.000119	CbGpPWpGaD
Pramipexole—ADRA2C—Signaling by GPCR—AKT1—liver cancer	6.11e-06	0.000119	CbGpPWpGaD
Pramipexole—DRD2—GPCR downstream signaling—AKT1—liver cancer	6.1e-06	0.000119	CbGpPWpGaD
Pramipexole—ADRA2A—Signaling by GPCR—PIK3CA—liver cancer	6.07e-06	0.000119	CbGpPWpGaD
Pramipexole—HTR2A—Signaling Pathways—CDKN1B—liver cancer	6.07e-06	0.000118	CbGpPWpGaD
Pramipexole—ADRA2B—Signaling Pathways—VEGFA—liver cancer	6.06e-06	0.000118	CbGpPWpGaD
Pramipexole—DRD2—Signaling Pathways—CASP3—liver cancer	6.05e-06	0.000118	CbGpPWpGaD
Pramipexole—DRD2—Signaling Pathways—IL2—liver cancer	6.04e-06	0.000118	CbGpPWpGaD
Pramipexole—ADRA2A—Signaling Pathways—RAF1—liver cancer	6.03e-06	0.000118	CbGpPWpGaD
Pramipexole—DRD2—Signaling by GPCR—IL6—liver cancer	6.01e-06	0.000117	CbGpPWpGaD
Pramipexole—HTR2A—GPCR downstream signaling—AKT1—liver cancer	6.01e-06	0.000117	CbGpPWpGaD
Pramipexole—ADRA2B—Signaling Pathways—STAT3—liver cancer	6e-06	0.000117	CbGpPWpGaD
Pramipexole—HTR1B—Signaling Pathways—PIK3CA—liver cancer	5.99e-06	0.000117	CbGpPWpGaD
Pramipexole—HTR2A—Signaling Pathways—CASP3—liver cancer	5.95e-06	0.000116	CbGpPWpGaD
Pramipexole—HTR2A—Signaling Pathways—IL2—liver cancer	5.94e-06	0.000116	CbGpPWpGaD
Pramipexole—HTR1D—Signaling Pathways—TP53—liver cancer	5.92e-06	0.000116	CbGpPWpGaD
Pramipexole—HTR2A—Signaling by GPCR—IL6—liver cancer	5.91e-06	0.000115	CbGpPWpGaD
Pramipexole—DRD4—Signaling Pathways—PIK3CA—liver cancer	5.9e-06	0.000115	CbGpPWpGaD
Pramipexole—DRD2—Signaling Pathways—CCND1—liver cancer	5.89e-06	0.000115	CbGpPWpGaD
Pramipexole—ADRA2A—Signaling Pathways—MTOR—liver cancer	5.89e-06	0.000115	CbGpPWpGaD
Pramipexole—ADRA2A—Signaling Pathways—PIK3CB—liver cancer	5.89e-06	0.000115	CbGpPWpGaD
Pramipexole—DRD2—Signaling Pathways—JUN—liver cancer	5.87e-06	0.000115	CbGpPWpGaD
Pramipexole—HTR1A—Signaling Pathways—VEGFA—liver cancer	5.85e-06	0.000114	CbGpPWpGaD
Pramipexole—DRD2—Signaling Pathways—CTNNB1—liver cancer	5.83e-06	0.000114	CbGpPWpGaD
Pramipexole—HTR2C—Signaling Pathways—VEGFA—liver cancer	5.82e-06	0.000113	CbGpPWpGaD
Pramipexole—HTR1B—Signaling Pathways—TP53—liver cancer	5.8e-06	0.000113	CbGpPWpGaD
Pramipexole—HTR2A—Signaling Pathways—CCND1—liver cancer	5.79e-06	0.000113	CbGpPWpGaD
Pramipexole—HTR1A—Signaling Pathways—STAT3—liver cancer	5.79e-06	0.000113	CbGpPWpGaD
Pramipexole—HTR2A—Signaling Pathways—JUN—liver cancer	5.78e-06	0.000113	CbGpPWpGaD
Pramipexole—DRD1—Signaling Pathways—KRAS—liver cancer	5.78e-06	0.000113	CbGpPWpGaD
Pramipexole—HTR2C—Signaling Pathways—STAT3—liver cancer	5.76e-06	0.000112	CbGpPWpGaD
Pramipexole—HTR2A—Signaling Pathways—CTNNB1—liver cancer	5.74e-06	0.000112	CbGpPWpGaD
Pramipexole—DRD2—Signaling Pathways—MMP9—liver cancer	5.72e-06	0.000112	CbGpPWpGaD
Pramipexole—DRD4—Signaling Pathways—TP53—liver cancer	5.71e-06	0.000111	CbGpPWpGaD
Pramipexole—DRD3—Signaling Pathways—KRAS—liver cancer	5.7e-06	0.000111	CbGpPWpGaD
Pramipexole—DRD2—Signaling Pathways—CDKN1A—liver cancer	5.69e-06	0.000111	CbGpPWpGaD
Pramipexole—HTR1D—Signaling Pathways—HRAS—liver cancer	5.66e-06	0.000111	CbGpPWpGaD
Pramipexole—ADRA2C—Signaling Pathways—VEGFA—liver cancer	5.66e-06	0.00011	CbGpPWpGaD
Pramipexole—HTR2B—Signaling Pathways—PIK3CA—liver cancer	5.63e-06	0.00011	CbGpPWpGaD
Pramipexole—HTR2A—Signaling Pathways—MMP9—liver cancer	5.62e-06	0.00011	CbGpPWpGaD
Pramipexole—ADRA2A—Signaling by GPCR—HRAS—liver cancer	5.62e-06	0.00011	CbGpPWpGaD
Pramipexole—HTR2A—Signaling Pathways—CDKN1A—liver cancer	5.6e-06	0.000109	CbGpPWpGaD
Pramipexole—ADRA2C—Signaling Pathways—STAT3—liver cancer	5.6e-06	0.000109	CbGpPWpGaD
Pramipexole—ADRA2B—Signaling Pathways—MYC—liver cancer	5.57e-06	0.000109	CbGpPWpGaD
Pramipexole—DRD2—Signaling Pathways—MAPK8—liver cancer	5.56e-06	0.000108	CbGpPWpGaD
Pramipexole—ADRA2B—Signaling Pathways—TGFB1—liver cancer	5.56e-06	0.000108	CbGpPWpGaD
Pramipexole—HTR1B—Signaling Pathways—HRAS—liver cancer	5.54e-06	0.000108	CbGpPWpGaD
Pramipexole—DRD2—Signaling by GPCR—AKT1—liver cancer	5.54e-06	0.000108	CbGpPWpGaD
Pramipexole—ADRA2A—Signaling Pathways—CDKN1B—liver cancer	5.52e-06	0.000108	CbGpPWpGaD
Pramipexole—HTR2A—Signaling Pathways—MAPK8—liver cancer	5.47e-06	0.000107	CbGpPWpGaD
Pramipexole—ADRA2A—GPCR downstream signaling—AKT1—liver cancer	5.46e-06	0.000107	CbGpPWpGaD
Pramipexole—DRD4—Signaling Pathways—HRAS—liver cancer	5.46e-06	0.000106	CbGpPWpGaD
Pramipexole—HTR2A—Signaling by GPCR—AKT1—liver cancer	5.45e-06	0.000106	CbGpPWpGaD
Pramipexole—HTR2B—Signaling Pathways—TP53—liver cancer	5.45e-06	0.000106	CbGpPWpGaD
Pramipexole—SLC22A2—Metabolism—PIK3CA—liver cancer	5.43e-06	0.000106	CbGpPWpGaD
Pramipexole—HTR1D—Signaling Pathways—IL6—liver cancer	5.42e-06	0.000106	CbGpPWpGaD
Pramipexole—ADRA2A—Signaling Pathways—CASP3—liver cancer	5.41e-06	0.000106	CbGpPWpGaD
Pramipexole—ADRA2A—Signaling Pathways—IL2—liver cancer	5.41e-06	0.000105	CbGpPWpGaD
Pramipexole—ADRA2A—Signaling by GPCR—IL6—liver cancer	5.38e-06	0.000105	CbGpPWpGaD
Pramipexole—HTR1A—Signaling Pathways—MYC—liver cancer	5.38e-06	0.000105	CbGpPWpGaD
Pramipexole—HTR1A—Signaling Pathways—TGFB1—liver cancer	5.36e-06	0.000105	CbGpPWpGaD
Pramipexole—HTR2C—Signaling Pathways—MYC—liver cancer	5.35e-06	0.000104	CbGpPWpGaD
Pramipexole—HTR2C—Signaling Pathways—TGFB1—liver cancer	5.34e-06	0.000104	CbGpPWpGaD
Pramipexole—DRD1—Signaling Pathways—PIK3CA—liver cancer	5.31e-06	0.000104	CbGpPWpGaD
Pramipexole—HTR1B—Signaling Pathways—IL6—liver cancer	5.31e-06	0.000104	CbGpPWpGaD
Pramipexole—ADRA2C—Metabolism—PIK3CA—liver cancer	5.28e-06	0.000103	CbGpPWpGaD
Pramipexole—ADRA2A—Signaling Pathways—CCND1—liver cancer	5.27e-06	0.000103	CbGpPWpGaD
Pramipexole—ADRA2A—Signaling Pathways—JUN—liver cancer	5.26e-06	0.000103	CbGpPWpGaD
Pramipexole—DRD3—Signaling Pathways—PIK3CA—liver cancer	5.24e-06	0.000102	CbGpPWpGaD
Pramipexole—DRD4—Signaling Pathways—IL6—liver cancer	5.22e-06	0.000102	CbGpPWpGaD
Pramipexole—ADRA2A—Signaling Pathways—CTNNB1—liver cancer	5.22e-06	0.000102	CbGpPWpGaD
Pramipexole—HTR2B—Signaling Pathways—HRAS—liver cancer	5.21e-06	0.000102	CbGpPWpGaD
Pramipexole—ADRA2C—Signaling Pathways—MYC—liver cancer	5.2e-06	0.000102	CbGpPWpGaD
Pramipexole—ADRA2C—Signaling Pathways—TGFB1—liver cancer	5.19e-06	0.000101	CbGpPWpGaD
Pramipexole—ADRA2B—Signaling Pathways—KRAS—liver cancer	5.15e-06	0.0001	CbGpPWpGaD
Pramipexole—DRD1—Signaling Pathways—TP53—liver cancer	5.14e-06	0.0001	CbGpPWpGaD
Pramipexole—DRD2—Signaling Pathways—VEGFA—liver cancer	5.13e-06	0.0001	CbGpPWpGaD
Pramipexole—ADRA2A—Signaling Pathways—MMP9—liver cancer	5.12e-06	9.98e-05	CbGpPWpGaD
Pramipexole—ADRA2A—Signaling Pathways—CDKN1A—liver cancer	5.1e-06	9.95e-05	CbGpPWpGaD
Pramipexole—DRD2—Signaling Pathways—STAT3—liver cancer	5.08e-06	9.92e-05	CbGpPWpGaD
Pramipexole—DRD3—Signaling Pathways—TP53—liver cancer	5.07e-06	9.89e-05	CbGpPWpGaD
Pramipexole—SLC22A1—Metabolism—PIK3CA—liver cancer	5.06e-06	9.88e-05	CbGpPWpGaD
Pramipexole—HTR2A—Signaling Pathways—VEGFA—liver cancer	5.05e-06	9.85e-05	CbGpPWpGaD
Pramipexole—HTR1D—Signaling Pathways—AKT1—liver cancer	5e-06	9.76e-05	CbGpPWpGaD
Pramipexole—HTR2A—Signaling Pathways—STAT3—liver cancer	5e-06	9.76e-05	CbGpPWpGaD
Pramipexole—HTR2B—Signaling Pathways—IL6—liver cancer	4.99e-06	9.73e-05	CbGpPWpGaD
Pramipexole—ADRA2A—Signaling Pathways—MAPK8—liver cancer	4.98e-06	9.71e-05	CbGpPWpGaD
Pramipexole—HTR1A—Signaling Pathways—KRAS—liver cancer	4.97e-06	9.7e-05	CbGpPWpGaD
Pramipexole—ADRA2A—Signaling by GPCR—AKT1—liver cancer	4.96e-06	9.68e-05	CbGpPWpGaD
Pramipexole—HTR2C—Signaling Pathways—KRAS—liver cancer	4.94e-06	9.65e-05	CbGpPWpGaD
Pramipexole—DRD1—Signaling Pathways—HRAS—liver cancer	4.91e-06	9.59e-05	CbGpPWpGaD
Pramipexole—HTR1B—Signaling Pathways—AKT1—liver cancer	4.9e-06	9.55e-05	CbGpPWpGaD
Pramipexole—DRD3—Signaling Pathways—HRAS—liver cancer	4.85e-06	9.46e-05	CbGpPWpGaD
Pramipexole—DRD4—Signaling Pathways—AKT1—liver cancer	4.82e-06	9.4e-05	CbGpPWpGaD
Pramipexole—ADRA2C—Signaling Pathways—KRAS—liver cancer	4.81e-06	9.38e-05	CbGpPWpGaD
Pramipexole—ADRA2B—Signaling Pathways—PIK3CA—liver cancer	4.73e-06	9.23e-05	CbGpPWpGaD
Pramipexole—DRD2—Signaling Pathways—MYC—liver cancer	4.72e-06	9.21e-05	CbGpPWpGaD
Pramipexole—DRD2—Signaling Pathways—TGFB1—liver cancer	4.71e-06	9.19e-05	CbGpPWpGaD
Pramipexole—DRD1—Signaling Pathways—IL6—liver cancer	4.7e-06	9.17e-05	CbGpPWpGaD
Pramipexole—HTR2A—Signaling Pathways—MYC—liver cancer	4.65e-06	9.07e-05	CbGpPWpGaD
Pramipexole—DRD3—Signaling Pathways—IL6—liver cancer	4.64e-06	9.05e-05	CbGpPWpGaD
Pramipexole—HTR2A—Signaling Pathways—TGFB1—liver cancer	4.63e-06	9.04e-05	CbGpPWpGaD
Pramipexole—HTR2B—Signaling Pathways—AKT1—liver cancer	4.6e-06	8.97e-05	CbGpPWpGaD
Pramipexole—ADRA2A—Signaling Pathways—VEGFA—liver cancer	4.59e-06	8.96e-05	CbGpPWpGaD
Pramipexole—ADRA2B—Signaling Pathways—TP53—liver cancer	4.58e-06	8.93e-05	CbGpPWpGaD
Pramipexole—HTR1A—Signaling Pathways—PIK3CA—liver cancer	4.57e-06	8.91e-05	CbGpPWpGaD
Pramipexole—ADRA2A—Signaling Pathways—STAT3—liver cancer	4.55e-06	8.88e-05	CbGpPWpGaD
Pramipexole—HTR2C—Signaling Pathways—PIK3CA—liver cancer	4.54e-06	8.86e-05	CbGpPWpGaD
Pramipexole—SLC22A2—Metabolism—AKT1—liver cancer	4.44e-06	8.66e-05	CbGpPWpGaD
Pramipexole—ADRA2C—Signaling Pathways—PIK3CA—liver cancer	4.42e-06	8.62e-05	CbGpPWpGaD
Pramipexole—HTR1A—Signaling Pathways—TP53—liver cancer	4.42e-06	8.62e-05	CbGpPWpGaD
Pramipexole—HTR2C—Signaling Pathways—TP53—liver cancer	4.39e-06	8.57e-05	CbGpPWpGaD
Pramipexole—ADRA2B—Signaling Pathways—HRAS—liver cancer	4.38e-06	8.54e-05	CbGpPWpGaD
Pramipexole—DRD2—Signaling Pathways—KRAS—liver cancer	4.36e-06	8.51e-05	CbGpPWpGaD
Pramipexole—DRD1—Signaling Pathways—AKT1—liver cancer	4.34e-06	8.46e-05	CbGpPWpGaD
Pramipexole—ADRA2C—Metabolism—AKT1—liver cancer	4.32e-06	8.42e-05	CbGpPWpGaD
Pramipexole—HTR2A—Signaling Pathways—KRAS—liver cancer	4.29e-06	8.38e-05	CbGpPWpGaD
Pramipexole—ADRA2A—Metabolism—PIK3CA—liver cancer	4.29e-06	8.37e-05	CbGpPWpGaD
Pramipexole—DRD3—Signaling Pathways—AKT1—liver cancer	4.28e-06	8.35e-05	CbGpPWpGaD
Pramipexole—ADRA2C—Signaling Pathways—TP53—liver cancer	4.27e-06	8.34e-05	CbGpPWpGaD
Pramipexole—ADRA2A—Signaling Pathways—MYC—liver cancer	4.23e-06	8.25e-05	CbGpPWpGaD
Pramipexole—HTR1A—Signaling Pathways—HRAS—liver cancer	4.22e-06	8.24e-05	CbGpPWpGaD
Pramipexole—ADRA2A—Signaling Pathways—TGFB1—liver cancer	4.22e-06	8.23e-05	CbGpPWpGaD
Pramipexole—HTR2C—Signaling Pathways—HRAS—liver cancer	4.2e-06	8.2e-05	CbGpPWpGaD
Pramipexole—ADRA2B—Signaling Pathways—IL6—liver cancer	4.19e-06	8.17e-05	CbGpPWpGaD
Pramipexole—SLC22A1—Metabolism—AKT1—liver cancer	4.14e-06	8.07e-05	CbGpPWpGaD
Pramipexole—ADRA2C—Signaling Pathways—HRAS—liver cancer	4.09e-06	7.98e-05	CbGpPWpGaD
Pramipexole—HTR1A—Signaling Pathways—IL6—liver cancer	4.04e-06	7.89e-05	CbGpPWpGaD
Pramipexole—HTR2C—Signaling Pathways—IL6—liver cancer	4.02e-06	7.85e-05	CbGpPWpGaD
Pramipexole—DRD2—Signaling Pathways—PIK3CA—liver cancer	4.01e-06	7.82e-05	CbGpPWpGaD
Pramipexole—HTR2A—Signaling Pathways—PIK3CA—liver cancer	3.94e-06	7.7e-05	CbGpPWpGaD
Pramipexole—ADRA2C—Signaling Pathways—IL6—liver cancer	3.91e-06	7.63e-05	CbGpPWpGaD
Pramipexole—ADRA2A—Signaling Pathways—KRAS—liver cancer	3.91e-06	7.62e-05	CbGpPWpGaD
Pramipexole—DRD2—Signaling Pathways—TP53—liver cancer	3.88e-06	7.57e-05	CbGpPWpGaD
Pramipexole—ADRA2B—Signaling Pathways—AKT1—liver cancer	3.86e-06	7.54e-05	CbGpPWpGaD
Pramipexole—HTR2A—Signaling Pathways—TP53—liver cancer	3.82e-06	7.45e-05	CbGpPWpGaD
Pramipexole—HTR1A—Signaling Pathways—AKT1—liver cancer	3.73e-06	7.28e-05	CbGpPWpGaD
Pramipexole—HTR2C—Signaling Pathways—AKT1—liver cancer	3.71e-06	7.24e-05	CbGpPWpGaD
Pramipexole—DRD2—Signaling Pathways—HRAS—liver cancer	3.71e-06	7.24e-05	CbGpPWpGaD
Pramipexole—HTR2A—Signaling Pathways—HRAS—liver cancer	3.65e-06	7.12e-05	CbGpPWpGaD
Pramipexole—ADRA2C—Signaling Pathways—AKT1—liver cancer	3.61e-06	7.04e-05	CbGpPWpGaD
Pramipexole—ADRA2A—Signaling Pathways—PIK3CA—liver cancer	3.59e-06	7e-05	CbGpPWpGaD
Pramipexole—DRD2—Signaling Pathways—IL6—liver cancer	3.55e-06	6.93e-05	CbGpPWpGaD
Pramipexole—ADRA2A—Metabolism—AKT1—liver cancer	3.51e-06	6.84e-05	CbGpPWpGaD
Pramipexole—HTR2A—Signaling Pathways—IL6—liver cancer	3.49e-06	6.82e-05	CbGpPWpGaD
Pramipexole—ADRA2A—Signaling Pathways—TP53—liver cancer	3.47e-06	6.77e-05	CbGpPWpGaD
Pramipexole—ADRA2A—Signaling Pathways—HRAS—liver cancer	3.32e-06	6.48e-05	CbGpPWpGaD
Pramipexole—DRD2—Signaling Pathways—AKT1—liver cancer	3.27e-06	6.39e-05	CbGpPWpGaD
Pramipexole—HTR2A—Signaling Pathways—AKT1—liver cancer	3.22e-06	6.29e-05	CbGpPWpGaD
Pramipexole—ADRA2A—Signaling Pathways—IL6—liver cancer	3.18e-06	6.2e-05	CbGpPWpGaD
Pramipexole—ADRA2A—Signaling Pathways—AKT1—liver cancer	2.93e-06	5.72e-05	CbGpPWpGaD
